Alain Beck | Senior Director
Centre d'Immunologie Pierre Fabre

Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology (dalotuzumab/IGF-1R licensed to Merck; telisotuzumab and telisotuzumab vedotin/cMet, licensed to AbbVie; h515H7/CXCR4 and W0101 ADC/IGF-1R), peptides and vaccines (RSV, ELA/P40). He has published +210 papers and reports on mAbs, biosimilars, biobetters, ADCs, bsAbs, Fc-fusions, protein scaffolds, structure/function relationships, stability, comparability and developability (h-index: 45; +8000 citations). He was involved in more than 280 scientific meetings (AIS, ASMS, BAS, CASSS, EAC, GlycoBiotec, HPLC, IBC, IMSC, ISC, PEGS, SEP, WADC, WBC) as chairperson, invited plenary/ keynote speaker, panelist, moderator, advisor, and organizer as well as to meetings and workshops with regulatory or standardization agencies (ANSM, EMA, EDQM/PhEur, FDA, PEI, USP, WHO). He was ranked 6/50 global antibody industry influencers (www.antibodysociety.org).

Appearances:



Festival of Biologics Day 1 @ 09:05

Chair's opening remarks

Festival of Biologics Day 1 @ 09:10

Antibody-based products successes and failures

Festival of Biologics Day 1 @ 16:30

Revisiting antibody-based products critical quality attributes with state-of-the art analytical methods

Festival of Biologics Day 1 @ 17:10

Cutting-Edge analytical methods for originator and biosimilar antibodies, Fc-fusion proteins and ADCs characterization

last published: 30/Jun/22 09:37 GMT

back to speakers